Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 809

Sort by

Sort Order Select

Journal Articles

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing

Elisabeth Ehrend, Patricia Manns, Sabine Harenkamp, Erhard Seifried, Christof Geisen, Halvard Bonig

Blood (2021) 138 (9): 814–817.

https://doi.org/10.1182/blood.2021011396

Published: 2021

Includes: Supplemental data

Journal Articles

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Vandana Chaturvedi, Rebecca A. Marsh, Adi Zoref-Lorenz, Erika Owsley, Vijaya Chaturvedi, Trung C. Nguyen, Jordana R. Goldman, Michael M. Henry, Jay N. Greenberg, Stephan Ladisch, Michelle L. Hermiston, Michael Jeng, Ahmed Naqvi, Carl E. Allen, Hector R. Wong, Michael B. Jordan

Blood (2021) 137 (17): 2337–2346.

https://doi.org/10.1182/blood.2020009499

Published: 2021

Includes: Supplemental data

Journal Articles

A GPI-Anchored Protein, CD109, Protects Hematopoietic Progenitor Cells from Erythroid Differentiation Induced By TGF-β

Tanabe Mikoto, MD, Nguyen Hoang Maianh, MD, Kohei Hosokawa, MD PhD, Noriharu Nakagawa, MD, Luis Espinoza, MD PhD, Hirohito Yamazaki, MD PhD, Shinji Nakao, MD PhD

Blood (2019) 134 (Supplement_1): 3736.

https://doi.org/10.1182/blood-2019-126677

Published: 2019

Journal Articles

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Milena Mazan, PhD, Marion Chapellier, PhD, Marcus Järås, PhD, Michal Mikula, MD PhD, Eliza Majewska, PhD, Katarzyna Wiklik, PhD, Michal Combik, PhD, Aniela Golas, PhD, Magdalena Masiejczyk, MSc, Elzbieta Fiedor, MSc, Federico Malusa, MSc, Przemyslaw Juszczynski, Prof., MD PhD, Magdalena Cybulska, DVM, Maciej Mikulski, PhD, Jerzy Ostrowski, Prof., MD PhD, Pawel Chrom, MD PhD, Krzysztof Brzózka, PhD, Tomasz Rzymski, PhD

Blood (2019) 134 (Supplement_1): 3774.

https://doi.org/10.1182/blood-2019-128073

Published: 2019

Journal Articles

The Locommotion Study (MMY4001): A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients with Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMiD, and CD38 Monoclonal Antibody Treatment and Documented Disease Progression

Blood (2019) 134 (Supplement_1): 5549.

https://doi.org/10.1182/blood-2019-122939

Published: 2019

Journal Articles

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Lingna Li, PhD, Wenyong Tong, PhD, Megan Lau, BS, Katherine Fells, PhD, Tong Zhu, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Zheng Yan, PhD, Dalun Deng, PhD, Ken Takeshita, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD

Blood (2019) 134 (Supplement_1): 5621.

https://doi.org/10.1182/blood-2019-132062

Published: 2019

Journal Articles

Establishment and Characterization of a Myeloma Cell Line- Aku-MY01

Sheerien Kareem Rajput, BSc,MSc, El-Nasir M A Lalani, BSc MBChB FRCPath PhDFHEA

Blood (2019) 134 (Supplement_1): 5535.

https://doi.org/10.1182/blood-2019-132238

Published: 2019

Journal Articles

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Emma Nolan, BSc, Arwen Stikvoort, PhD, Mark Gurney, MD, Nutsa Burduli, BSc, Lucy Kirkham-McCarthy, MSc, John Daly, MSc, Niels W. C. J. Van De Donk, Tuna Mutis, MD PhD, Subhashis Sarkar, PhD, Michael E O'Dwyer, MD

Blood (2019) 134 (Supplement_1): 5536.

https://doi.org/10.1182/blood-2019-128605

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Identification of an Expanded Immature Cell Population in Human Bone Marrow during Erythroid Responses to ESA Treatment

Isabel Juliana F Hofman, PhD, Teresa Mortera-Blanco, PhD, Sigita Venckute Larsson, Sten Eirik Waelgaard Jacobsen, MD PhD, Petter S Woll, PhD, Marios Dimitriou, PhD, Eva Hellstrom Lindberg, MD PhD

Blood (2019) 134 (Supplement_1): 2993.

https://doi.org/10.1182/blood-2019-130065

Published: 2019

Journal Articles

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Daniel Helbig, MD, Ghaith Abu Zeinah, MD, Erica B Bhavsar, BS, Richard R. Furman, MD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 3025.

https://doi.org/10.1182/blood-2019-125426

Published: 2019

Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4313.

https://doi.org/10.1182/blood-2019-123600

Published: 2019

Journal Articles

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

Aki Yanagi, MS, Naohiro Tsuyama, PhD, Misaki Sugai, BS, Yu Abe, PhD, Yusuke Azami, MD, Yukari Yanai, MS, Akinobu Ota, PhD, Karnan Sivasundaram, PhD, Moe Muramatsu, BS, Tomonari Shigemura, MD PhD, Megumi Sasatani, PhD, Yuko Hashimoto, MD PhD, Kenji Kamiya, MD PhD, Ichiro Hanamura, MD PhD, Takayuki Ikezoe, MD PhD, Masafumi Onodera, MD PhD, Akira Sakai, MD PhD

Blood (2019) 134 (Supplement_1): 3057.

https://doi.org/10.1182/blood-2019-122344

Published: 2019

Journal Articles

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

Lijie Xing, MD, Yuyin Li, PhD, Liang Lin, PhD, Tengteng Yu, MD PhD, Kenneth Wen, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 3096.

https://doi.org/10.1182/blood-2019-127135

Published: 2019

Journal Articles

The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells

Eric Robert Fedyk, BSc, MSc, PhD, Neeraja Idamakanti, BVSc MSc DVM, Jia Chen, BSc, MSc, PhD, Jose Estevam, BSc MSc, Vivian Hernandez, BSc PhD, Matthew Wagoner, BSc PhD, Mary Carsillo, BSc DVM PhD, Deborah Berg, RN, MSN, Kristina Allikmets, MD PhD, Gezim Lahu, BSc MSc PhD, Antonio Palumbo, MD

Blood (2019) 134 (Supplement_1): 3136.

https://doi.org/10.1182/blood-2019-128238

Published: 2019

Journal Articles

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

Bart ECG De Goeij, PhD, Maarten L Janmaat, PhD, Grietje Andringa, Laurens Kil, Berris Van Kessel, Kristine A. Frerichs, MD, Andreas Lingnau, Andreas Freidig, Tuna Mutis, MD PhD, A. Kate Sasser, Esther C. W. Breij, Niels W. C. J. Van De Donk, MD PhD, Tahamtan Ahmadi, David Satijn

Blood (2019) 134 (Supplement_1): 3106.

https://doi.org/10.1182/blood-2019-125788

Published: 2019

Journal Articles

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Jode P Goodridge, PhD, Sajid Mahmood, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Jason Dinella, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Uta Hopken, Armin Rehm, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 3214.

https://doi.org/10.1182/blood-2019-131373

Published: 2019

Journal Articles

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frank Cichocki, PhD, Karrune Woan, MD PhD, Cheng-Ying Wu, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 3215.

https://doi.org/10.1182/blood-2019-124490

Published: 2019

Journal Articles

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Guido J. Tricot, MD PhD, Doug Steward, Susan Panozzo, Jeffery R. Sawyer, Brian A Walker, PhD, Joshua Epstein, DSc, Faith E. Davies, MD, Gareth Morgan, MD PhD, Adam Rosenthal, MS, Antje Hoering, PhD, Katherine K Nishimura, Bart Barlogie, MD PhD

Blood (2019) 134 (Supplement_1): 3309.

https://doi.org/10.1182/blood-2019-131870

Published: 2019

Journal Articles

Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients

Alice Bettelli, MS, Rita Ruggiano, Silvia Bocchi, Laura Rocchi, PhD, Andrea Faenza, PhD, Enrica Borsi, Carolina Terragna, Elena Zamagni, MD, Marina Martello, Marco Bettelli, Laura Rambelli, Viviana Guadagnuolo, Nicola Pecorari, Luca Giulianelli, Matteo Pisani, Dario Biscarini, Michele Cavo, Roberto Guerrieri, Massimo Bocchi, PhD

Blood (2019) 134 (Supplement_1): 3372.

https://doi.org/10.1182/blood-2019-126894

Published: 2019

NARROW

Preanalytic depletion of medicinal anti-CD38 antibody from patient plasma for immunohematology testing

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

A GPI-Anchored Protein, CD109, Protects Hematopoietic Progenitor Cells from Erythroid Differentiation Induced By TGF-β

CDK8 Inhibitors Induce Transcriptional Reprogramming of AML Cells Associated with Differentiation

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Establishment and Characterization of a Myeloma Cell Line- Aku-MY01

Targeting CD38 high Acute Myeloid Leukaemia with "Affinity Optimized" Chimeric Antigen Receptor and Membrane Bound TRAIL Expressing Natural Killer Cells

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Identification of an Expanded Immature Cell Population in Human Bone Marrow during Erythroid Responses to ESA Treatment

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL)

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Introduction of Chromosomal Translocation t(11; 14) and a p53 Deletion into Normal B Cell-Derived iPSCs to Elucidate the Cellular Origin of Myeloma Cells

MEDI2228, a Novel Bcma Antibody-PBD Conjugate, Sensitizes Human Multiple Myeloma Cells to NK Cell-Mediated Cytotoxicity and Upregulates CD38 Expression in MM Cells

The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells

Hexabody-CD38, a Novel CD38 Antibody with a Hexamerization Enhancing Mutation, Demonstrates Enhanced Complement-Dependent Cytotoxicity and Shows Potent Anti-Tumor Activity in Preclinical Models of Hematological Malignancies

FT576: A Novel Multiplexed Engineered Off-the-Shelf Natural Killer Cell Immunotherapy for the Dual-Targeting of CD38 and Bcma for the Treatment of Multiple Myeloma

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups

Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only